Previous symbols: NGL. Aliases: NEU, HER-2, CD340, HER2, c-ERB2, c-ERB-2, MLN-19, p185(erbB2).
Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.
| Disorder | Relationship | Where the gene appears |
|---|---|---|
| Familial Visceral Neuropathy 2 | causative germline loss of function |
mechanism: Biallelic ERBB2 Kinase-Domain Variant
|
| Gastric Adenocarcinoma | somatic driver somatic |
mechanism: Receptor Tyrosine Kinase Amplification
subtype: CIN
biochemical: HER2 (ERBB2) Overexpression or Amplification
scoped to subtype: CIN
|
| Thymic Neuroendocrine Carcinoma | biomarker somatic | |
| Breast Carcinoma |
untyped
Amplification or overexpression
somatic
|
|
| Cervical Adenocarcinoma |
untyped
Somatic Mutation / Amplification
|
|
| Endometrial Carcinoma |
untyped
Somatic amplification or overexpression
|
scoped to subtype: Copy-Number High p53-Abnormal
|
| Esophageal Adenocarcinoma |
untyped
Somatic Amplification
|
|
| Esophageal Carcinoma |
untyped
Somatic Amplification
|
|
| Ethmoid Sinus Adenocarcinoma |
untyped
Not amplified or overexpressed
|
|
| Gallbladder Cancer |
untyped
Somatic Amplification/Activating Mutation
|
|
| HER2-Positive Breast Cancer |
untyped
Somatic Amplification
|
|
| Ovarian Mucinous Carcinoma |
untyped
HER2 gene amplification/overexpression in a targetable subset
|
|
| BRAF V600E-Mutant Non-Small Cell Lung Cancer | no genetic record |
mechanism: MAPK Reactivation and Bypass Resistance
|
| Small Intestine Cancer | no genetic record |
subtype: Adenocarcinoma
|
| Vulvar Adenocarcinoma | no genetic record |
mechanism: HER2-Positive EMPD Signaling (Cross-Site Case Evidence)
|
Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.